Cytek Biosciences, Inc.

Cytek Biosciences, Inc. announced that Valerie Barnett will step down from her role as Chief Legal Officer and Corporate Secretary, effective June 29, 2026. The company stated that her departure is not a result of any disagreement with its operations, policies, or practices.

Cytek Biosciences unveiled its new 7-laser Cytek Borealis full spectrum flow cytometer and automation-ready configurations of the Cytek Aurora Evo system at CYTO 2026. The Borealis system features 120 detectors across seven laser lines, including new Deep Ultraviolet and Infrared lasers, enabling high-resolution 60-color panels and integrating future cellular imaging capabilities. The Aurora Evo enhancements aim to streamline high-dimensional workflows by enabling integration with robotic systems, particularly beneficial for biopharma and CROs. Cytek will also host two tutorial sessions as a Platinum sponsor at the conference.

Cytek Biosciences, Inc. announced that Philippe Busque, Ph.D., Senior Vice President, Global Sales and Services, submitted his resignation on May 27, 2026. His departure is effective June 5, 2026, as he pursues another career opportunity. The company stated that Dr. Busque's resignation is not due to any disagreement with its operations, policies, or practices.

Cytek Biosciences reported a significant increase in net loss for Q1 2026, reaching $(18.9) million, compared to $(11.4) million in Q1 2025. Despite this, total revenue grew by 6.5% to $44.1 million, driven by strong service revenue growth. The company also saw an increase in cash used in operating activities and a decrease in cash and cash equivalents.

Cytek Biosciences reported its first quarter 2026 financial results, with total revenue increasing 6% year-over-year to $44.1 million. Service revenue saw a 15% increase, and recurring revenue grew to 35% of total revenue on a trailing-12-month basis. Despite revenue growth and an expanding installed base, the company experienced a wider net loss of $18.9 million and an adjusted EBITDA loss of $9.1 million, primarily due to increased general and administrative expenses. Cytek Biosciences reaffirmed its full-year 2026 revenue guidance of $205 million to $212 million.

Cytek Biosciences, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 10, 2026. Stockholders will vote on the election of three Class II director nominees, including new nominee Glenn P. Muir, for terms expiring in 2029. Additionally, they will cast a non-binding advisory vote on executive compensation for 2025 and ratify Deloitte & Touche LLP as the independent auditor for 2026.